A candidate for the Chinese Covid-19 vaccine, BBIBP-CorV, which is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, according to a study published in The Lancet.
A previous clinical trial reported similar results for another vaccine, which is also based on inactivated whole SARS-CoV-2 virus, but in this study the vaccine was only tested on people under 60 years of age.
The latest study, reported in the journal Lancet Infectious Diseases, included participants between the ages of 18 and 80 and found that antibody responses were elicited in all recipients.
Participants over 60 years of age responded more slowly, taking 42 days before antibodies were detected in all recipients, compared with 28 days for participants aged 18-59 years.
“Protecting the elderly is a key goal of the successful Covid-19 vaccine, as this age group has a higher risk of severe disease,” said study author Xiaoming Yang of the Beijing Institute of Biological Products Company Limited in China.
However, sometimes vaccines are less effective in this group because the immune system weakens with age.
“It is therefore encouraging to see that BBIBP-CorV elicits antibody reactions in people 60 years of age and older, and we believe that this justifies further investigation,” Ian added.
The BBIBP-CorV vaccine used in the study reported here is based on a sample of the virus that was isolated from a patient in China.
Stocks of the virus were grown in the laboratory using cell lines and then inactivated with a chemical called beta-proprionolactone.
BBIBP-CorV includes a killed virus mixed with another component, aluminum hydroxide, which is called an adjuvant because it is known to enhance immune responses.
The first phase of the study was designed to find the optimal safe dose for BBIBP-CorV.
It was attended by 96 healthy volunteers aged 18 to 59 years and the second group of 96 participants aged 60 to 80 years.
In each group, the vaccine was tested at three different dose levels, and two vaccinations were given on day zero and day 28.
The fourth group in each age group (24 participants in each age group) received two doses of placebo vaccine. In total, in phase 1 of the study, 144 participants received the vaccine and 48 received the placebo.
The second phase of the study was designed to determine the optimal vaccination schedule.
Participants were asked to report any adverse events during the first seven days after each vaccination, and were tested by the study team.
“No serious adverse events were reported within 28 days of final vaccination. No clinically significant changes in organ function detected during laboratory tests were reported in any of the groups,” the authors wrote.
The latest information about OTT / Streaming Content, Home Delivery!